Industry Expertise-arkiv - Page 3 of 4 - Biosector Ltd.

Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.

by Stefan Sandström

MAH, DMAH, or a Japanese Partner: A Strategic Choice You Need to Make Before Entering Japan

Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]

0

Illustration of the supply chain for targeted alpha therapy in Japan using Astatine-211. The graphic shows domestic cyclotron production, GMP radiochemistry and automated purification, a national site network strategy, time-critical logistics across Japan due to the 7.2-hour half-life, and outpatient administration of the radiopharmaceutical.

by Stefan Sandström

Targeted Alpha Therapy in Japan: why Domestic ²¹¹At Supply Matters for Scale

Radioligand therapy is now a board-level topic in Japan, not because the science is new, but […]

0

Abstract wide illustration showing Japan drug pricing from listing to post-launch revisions, using blue shapes on a sand background with red trigger markers.

by Stefan Sandström

December 15, 2025

Japan FY2026 Drug Pricing Reform Draft: What Changes at Listing, What Tightens After Launch

On December 12, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) tabled a draft outline […]

0

Photorealistic scene of a consultant in a Tokyo meeting room connecting a foreign company with Japanese pharma executives.

by Stefan Sandström

December 11, 2025

Why Japanese Targets Like You, Listen to You – and Still You Don’t Succeed

You fly in, you present, you charm the room. Heads nod. The technical team likes your […]

0

Abstract landscape of sand-toned islands linked by light-blue channels, with dark-blue bio-factory shapes and red markers suggesting biologics flow across Japanese hubs.

by Stefan Sandström

October 14, 2025

Japan’s Biotech Surge: How You Can Convert the Startup Boom into Revenue

A New Order is taking shape in Japan’s life sciences. Conference floors are packed, university benches […]

0

Two executives in a golden-yellow meeting room lean over a large sheet of paper spread across the table. They are animatedly pointing and gesturing, immersed in discussion, as if the printed spreadsheet in front of them holds the key to their success in Japan’s pharma market.

by Stefan Sandström

September 19, 2025

Essential Gateways to Japan’s Pharma Ecosystem

An A3 Executive Reference (2 pages) Japan rewards programs that are sequenced, evidenced, and locally socialized. […]

0

Two smiling businesswomen in an office with a view of Tokyo, collaborating on a whiteboard with flowcharts and a large corkboard filled with colorful sticky notes.

by Stefan Sandström

September 15, 2025

Japan’s Pharma Ecosystem

Cracking Japan’s Pharma Ecosystem: Field Notes from ~20 Years in the Trenches Japan rewards sequencing, proof, […]

0

Illustration showing Japan's pharmaceutical market decline with red arrow, pills, and bar graph.

by Stefan Sandström

The Rise and Fall of Japan’s Global Pharmaceutical Market Share

In the mid-1990s, Japan was not merely participating in the global pharmaceutical industry—it was shaping it. […]

0

Abstract illustration representing Japan’s SaMD commercialization ecosystem.

by Stefan Sandström

SaMD Commercialization in Japan: Strategic Opportunities Beyond Approval

Japan is the fourth-largest global medical device market, with its healthcare system actively integrating digital tools […]

0

Speaker presenting at the launch event of TOBU on-demand biobank in Japan.

by Stefan Sandström

Translating Potential: Bridging Biomedical Research and Industry in Japan

Some of Japan’s most forward-thinking minds gathered to scrutinise Japan’s biobank conundrum at Shonan iPark. In […]

0